Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Target Oncol. 2019 Oct;14(5):563–575. doi: 10.1007/s11523-019-00662-4

Figure 7.

Figure 7.

Ex-vivo kinome profile and protein expression of Raji xenograft tumors. (a) MIB/MS kinome profile of Raji xenograft tumors on treatment with cyclophosphamide, MLN8237, or combination of cyclophosphamide and MLN8237 for 3, 10, or 30 days. Average, mean-centered log2 fold change was used for unsupervised hierarchical clustering. (b) MIB binding (LFQ intensity) focused on AURK A and B in Raji xenograft tumors on treatment with MLN8237 for 3, 10, or 30 days. (c) The sum log2 fold changes in response to MLN8237 treatment on days 3 and 10 in Raji xenograft tumors are shown as a stacked bar plot. (d) Src family protein expression levels by immunoblotting in Raji xenograft tumors on treatment with MLN8237 for 0, 3, 7, or 25 days. HT DLBCL cell line was used as a positive control for Src overexpression. (e) Kinome expression profile (log2 fold change versus untreated) focused on the kinases upregulated in response to MLN8237 treatment on days 3, 10, and 30 in Raji xenograft tumors.